NEO Logo

NeoGenomics, Inc. (NEO) 

NASDAQ
Market Cap
$2.2B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
370 of 774
Rank in Industry
25 of 42

Largest Insider Buys in Sector

NEO Stock Price History Chart

NEO Stock Performance

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence …

Insider Activity of NeoGenomics, Inc.

Over the last 12 months, insiders at NeoGenomics, Inc. have bought $0 and sold $248,973 worth of NeoGenomics, Inc. stock.

On average, over the past 5 years, insiders at NeoGenomics, Inc. have bought $520,710 and sold $20.36M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 17,000 shares for transaction amount of $520,710 was made by Mallon Mark (Chief Executive Officer) on 2021‑12‑06.

List of Insider Buy and Sell Transactions, NeoGenomics, Inc.

2024-11-15SaleGeneral Counsel
5,175
0.0039%
$15.36$79,475+2.33%
2024-08-15SaleGeneral Counsel
1,040
0.0008%
$16.05$16,6950.00%
2024-05-15SaleGeneral Counsel
1,049
0.0009%
$15.74$16,511-2.18%
2024-03-04Saledirector
6,112
0.0048%
$15.97$97,579-7.59%
2024-02-15SaleGeneral Counsel
2,587
0.002%
$14.96$38,713+0.10%
2023-11-17SaleGeneral Counsel
2,669
0.002%
$18.39$49,083-20.26%
2022-03-07SaleChief Financial Officer
3,209
0.0026%
$18.29$58,693-43.84%
2021-12-21SaleChief Financial Officer
1,846
0.0015%
$35.00$64,610-70.51%
2021-12-06PurchaseChief Executive Officer
17,000
0.0137%
$30.63$520,710-67.38%
2021-11-26SaleChief Strategy Officer
33,334
0.0279%
$36.85$1.23M-71.51%
2021-11-24SaleChief Strategy Officer
33,333
0.0272%
$36.84$1.23M-72.23%
2021-11-24SalePresident, Informatics
25,000
0.0206%
$37.13$928,250-72.23%
2021-11-23SaleChief Strategy Officer
33,333
0.0277%
$37.19$1.24M-71.94%
2021-06-08Saledirector
20,734
0.0173%
$41.46$859,632-18.52%
2021-06-03SalePresident, Pharma Services
31,107
0.0263%
$40.11$1.25M-13.21%
2021-06-02SalePresident, Pharma Services
169,230
0.1436%
$40.39$6.84M-12.99%
2021-05-25SalePresident, Clinical Services
130,604
0.1108%
$39.31$5.13M-3.93%
2020-12-14Saledirector
25,000
0.0229%
$51.67$1.29M-11.37%
2020-12-14SaleChief Medical Officer
20,200
0.0183%
$51.06$1.03M-11.37%
2020-12-11Saledirector
25,000
0.0229%
$50.52$1.26M-8.99%

Insider Historical Profitability

24.79%
TETRAULT LYNN A.director
50062
0.039%
$17.1123+1.24%
KINDERHOOK, LP10 percent owner
4848334
3.7771%
$17.1150+67.31%
VAN OORT DOUGLAS MChairman and CEO
2422790
1.8875%
$17.11108+14.04%
CARDOZA GEORGEPresident, Pharma Services
176772
0.1377%
$17.11212+53.1%
SHOVLIN ROBERT J.President, Clinical Services
150101
0.1169%
$17.11111+4.82%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$312.06M15.5419.85M-0.65%-$2.05M0.01
The Vanguard Group$223.4M11.1314.21M+0.29%+$650,084.88<0.01
Brown Advisory$152.01M7.579.67M+0.27%+$411,486.720.2
T Rowe Price Investment Management Inc$107.8M5.376.86M+7.44%+$7.47M0.07
Janus Henderson$98.73M4.926.28M-1.07%-$1.06M0.05
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.